Arcturus Therapeutics to Present at Upcoming Investor Conference

Rhea-AI Summary

Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will engage in a panel discussion at the 13th Annual Biotech Showcase™ Investor Conference.

The discussion, titled COVID-19 Vaccines: All things impacted by COVID-19, will occur on January 11, 2020, at 1:00 p.m. ET. The event can be accessed on-demand from January 12 to March 31, 2020, via the event platform.

Arcturus specializes in mRNA medicines, with a diverse pipeline addressing COVID-19, Influenza, and rare diseases.

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will participate in a panel discussion taking place at the 13^th Annual Biotech Showcase™ Investor Conference:

Infectious Disease - COVID-19 Vaccines: All things impacted by COVID-19: The pursuit for an effective vaccine developed at a pandemic pace

• Panel Discussion
• Date: Monday, Jan 11, 2020
• Time: 1:00 p.m. ET, on-demand Jan 12-March 31 on the event’s platform, partneringONE
• Conference Link

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes self-replicating mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, Cystic Fibrosis, and Cardiovascular Disease along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (205 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation. For more information visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210106005325/en/

FAQ

What is the date of the Arcturus panel discussion at the Biotech Showcase?

The Arcturus panel discussion will take place on January 11, 2020.

What time will the Arcturus discussion on COVID-19 vaccines be held?

The discussion will be held at 1:00 p.m. ET.

Where can I watch the Arcturus panel discussion?

The panel discussion can be accessed on-demand from January 12 to March 31, 2020, on the partneringONE platform.

What topics will be covered in the Arcturus panel discussion?

The panel discussion will focus on COVID-19 vaccines and related impacts.

What is the significance of Arcturus Therapeutics in mRNA vaccine development?

Arcturus is a leading clinical-stage company developing mRNA vaccines for COVID-19 and other infectious diseases.